Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: J05A

Epclusa(sofosbuvir;velpatasvir)

Hepatitis C, Chronic

Marketing Authorisation Holder: Gilead Sciences Ireland UC

EMA Authorisation: 06/07/2016

INN: sofosbuvir;velpatasvir

Indication

Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Epclusa — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.